Please login to the form below

Not currently logged in

AbbVie begins 'first-of-its-kind' hep C charity pilot

Will work with Addaction Cornwall and The Hepatitis C Trust

Hepatits C AbbVie NHS partnership
Addaction's David Baldock (left) and Len Gooblar, head of strategic health initiatives at AbbVie

AbbVie is piloting a new UK programme to validate different approaches to improving hepatitis C testing and treatment in those with a history of injection drug use.

The pharma company will partner with two charities on the programme, which it described as 'a first-in-class pilot' that will use an evidence-based approach encompassing workforce training, peer-to-peer education and buddying (one-on-one support that helps people through their hospital and treatment journey).

Drug users are a typically hard to reach population who find it difficult to access traditional models of care.

AbbVie, Addaction Cornwall - the local branch of the national drug and alcohol charity, and The Hepatitis C Trust are hoping that the successful completion of their pilot programme will be followed by a national roll-out in 2015.

It is estimated that in England there are 160,000 people living with chronic hepatitis C infection, 19,705 of them in the South West, and 1,398 in Cornwall.
Sue Clark, operations director, Addaction Cornwall, said: “We are proud to be leading the way in piloting a ground-breaking partnership programme to improve the health of our communities, while contributing toward a longer-term vision of eliminating the hepatitis C virus (HCV) in the South West.”
Beyond testing and treating people with a history of injection drug use, the new programme hopes to free up NHS resources and reduce community-acquired transmission of hepatitis C.

Article by
Tara Craig

7th August 2014

From: Healthcare



Featured jobs

Subscribe to our email news alerts


Add my company
90TEN Healthcare

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...